Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

被引：0
|
作者：
Even, C. [1 ]
Bernard-Tessier, A. [2 ]
Texier, M. [3 ]
Said, O. Ben [4 ]
Iacob, M. [5 ]
Daste, A. [6 ]
Fayette, J. [7 ]
Zanetta, S. [8 ]
Lefebvre, G. [9 ]
Vinches, M. [10 ]
Johnson, A. C. [11 ]
Le Moal, L. Bozec [12 ]
Saada, E. B. [13 ]
Jallut, I. [14 ]
Garic, F. [15 ]
Monard, L. [16 ]
Bourhis, J. [17 ]
Guigay, J. [18 ]
Auperin, A. [19 ]
Ammari, S. [20 ]
机构：
[1] Inst Gustave Roussy, Head & Neck Oncol Dept, Villejuif, France
[2] Inst Gustave Roussy, Oncol Dept, Villejuif, France
[3] Inst Gustave Roussy, Biostat & Epidemiol, Villejuif, France
[4] Gustave Roussy, Radiol, Canc Campus, Villejuif, France
[5] IRO Reg Inst Oncol, Med Oncol Dept, Villejuif, France
[6] CHU Bordeaux, Med Oncol Dept, Hop St Andre, Bordeaux, France
[7] Ctr Leon Berard, Med Oncol Dept, Lyon, France
[8] Ctr Georges Francois Leclerc Dijon, Med Oncol Dept, Dijon, France
[9] Ctr Oscar Lambret, Med Oncol Dept, Lille, France
[10] ICM Inst Canc Montpellier, Med Oncol Dept, Montpellier, France
[11] Ctr Francois Baclesse, Med Oncol Dept, Caen, France
[12] Hop Rene Huguenin, Inst Curie, Med Oncol Dept, St Cloud, France
[13] Ctr Anticancer Antoine Lacassagne, Med Oncol, Nice, France
[14] Unicancer, R&D, Paris, France
[15] Unicancer, Paris, France
[16] Unicancer, UCGI R&D, Paris, France
[17] CHU Vaudois, Radiat Oncol Dept, UNIL CHUV, Lausanne, Switzerland
[18] Ctr Anticancer Antoine Lacassagne, Med Oncol Dept, Nice, France
[19] Gustave Roussy, Biostat & Epidemiol, Canc Campus, Villejuif, France
[20] Gustave Roussy, Med Oncol Dept, Canc Campus, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.799
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
675P
引用
收藏
页码：S851 / S851
页数：1
相关论文
共 50 条
  • [21] Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma
    Hanna, Glenn J.
    Oakley, Liam B.
    Shi, Ruichao
    ONeill, Anne
    Shin, Kee-Young
    Sehgal, Kartik
    Dennis, Michael J.
    Jo, Vickie Y.
    Wong, Kristine S.
    Haddad, Robert I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
    Hanna, Glenn J.
    Oakley, L. B.
    Shi, R.
    Oneill, A.
    Shin, K. Y.
    Scarfo, N.
    Sehgal, K.
    Dennis, M. J.
    Quinn, N.
    Jo, V. Y.
    Wong, K.
    Shvyrkova, A.
    Kushnarev, V.
    Shanthappa, B. U.
    Tkachuk, A.
    Kryukov, K.
    Sarachakov, A.
    Svekolkin, V.
    Lennerz, J.
    Waters, S.
    Haddad, R. I.
    CLINICAL CANCER RESEARCH, 2025, 31 (04) : 619 - 627
  • [23] Evaluation of systemic inflammatory response (SIR) markers in recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Pogorzelski, M.
    Hilser, T.
    Ting, S.
    Vossebein, I
    Gauler, T. C.
    Abendroth, A.
    Lang, S.
    Stuck, B.
    Abu-Jawad, J.
    Stuschke, M.
    Schmid, K. W.
    Schuler, M.
    Kasper, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 307 - 308
  • [24] Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)
    Jose Echarri, Maria
    Lopez-Martin, Ana
    Hitt, Ricardo
    CANCERS, 2016, 8 (03)
  • [25] To test, or not to test, that is the question: A real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Black, Chris M.
    Hair, Gleicy
    Zheng, Dandan
    Ai, Lei
    Wang, Liya
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Siu, L. L.
    Burtness, B.
    Cohen, E. E.
    Harrington, K. J.
    Licitra, L. F.
    Rischin, D.
    Zhu, Y.
    Okpara, C. E.
    Pinheiro, C.
    Swaby, R. F.
    Machiels, J-P.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S684
  • [27] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
    Shi, Y-K.
    Gao, L.
    Tian, Y.
    Chen, J.
    Wang, J.
    Bai, C.
    Li, X.
    Su, H.
    Liu, Z.
    ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
  • [28] Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012
    Chow, L.
    Mehra, R.
    Haddad, R.
    Gupta, S.
    Weiss, J.
    Berger, R.
    Burtness, B.
    Tahara, M.
    Keam, B.
    Le, D.
    Cheng, J.
    Heath, K.
    Pathiraja, K.
    Seiwert, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S579 - S579
  • [29] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
  • [30] Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 treatment naive patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
    Cohen, Ezra
    Bishnoi, Sarwan
    Laux, Douglas E.
    Wong, Deborah
    Amin, Asim
    Nabell, Lisle
    Schmidt, Emmett V.
    Xing, Biao
    Leung, Abraham C.
    Janssen, Robert
    CANCER RESEARCH, 2018, 78 (13)
12345